MedTrace Logo

Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer

NCT02810873 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2025-05-04

Study results available
· View outcomes & findings →

Summary

This clinical trial studies positron emission tomography imaging in using copper Cu 64 TP3805in patients with breast cancer. Diagnostic procedures, such as positron emission tomography (PET) and positron emission mammography (PEM) scan, using Cu-64-TP3805 may help doctors find and diagnose breast cancer.

Conditions

  • Breast Carcinoma

Interventions

DEVICE

Positron Emission Mammography

Undergo PEM Positron Emission Mammography scan

DEVICE

Positron Emission Tomography

Undergo PET Positron Emission Tomography scan

RADIATION

Fludeoxyglucose F-18

Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan

DRUG

Copper Cu 64 TP3805

Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    lead OTHER

Principal Investigators

  • Madhukar Thakur, PhD · Thomas Jefferson University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-05-31
Completion
2012-07-31
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02810873 on ClinicalTrials.gov